Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy
12 juin 2023 07h30 HE
|
Vaccitech plc
OXFORD, United Kingdom, June 12, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of...
[2023-2028] Bioprocess Technology Market Share Report – Reach $77.09 Billion by 2028 with 16.8% CAGR | Exclusive Research by The Insight Partners
09 juin 2023 10h07 HE
|
The Insight Partners
Pune, India, June 09, 2023 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Bioprocess Technology Market Share Report, Growth, Size, Revenue, Strategy, Industry Trends...
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
01 juin 2023 08h00 HE
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
Evaxion to host R&D Day on May 25, 2023
16 mai 2023 05h47 HE
|
Evaxion Biotech
COPENHAGEN, Denmark, May 16, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the discovery and...
Eviden, ColibrITD et l'ONERA créent la première plateforme de calcul quantique hybride dédiée à la combustion
16 mai 2023 04h00 HE
|
Atos International
Paris, France – May 16, 2023 – Eviden, an Atos business, ColibrITD and ONERA today announce the launch of VulQain, a research project, funded by the French Defense Innovation Agency, to build the...
Eviden, ColibrITD and ONERA join forces to build the first hybrid quantum combustion platform
16 mai 2023 04h00 HE
|
Atos International
Paris, France – May 16, 2023 – Eviden, an Atos business, ColibrITD and ONERA today announce the launch of VulQain, a research project, funded by the French Defense Innovation Agency, to build the...
Phathom Pharmaceuticals Reports First Quarter 2023 Results
10 mai 2023 08h00 HE
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., May 10, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
Phathom Pharmaceuticals Presents New Data at Digestive Disease Week® (DDW) 2023
09 mai 2023 08h00 HE
|
Phathom Pharmaceuticals
Higher H. pylori eradication rates demonstrated with vonoprazan-based regimens vs. lansoprazole triple therapy, regardless of different baseline demographics and clinical characteristicsMeta-analysis...
OpGen’s Subsidiary Curetis Signs Expansion of R&D Collaboration with FIND
05 avr. 2023 07h30 HE
|
OpGen, Inc.
Parties add several deliverables to initial R&D collaboration contractOverall potential revenue increased to up to euro 830 thousand ROCKVILLE, Md., April 05, 2023 (GLOBE NEWSWIRE) -- OpGen,...
NGen lance un nouveau fonds de 35 millions de dollars pour les projets de pointe dans le domaine de la fabrication avancée
27 mars 2023 12h00 HE
|
Next Generation Manufacturing Canada (NGen)
NGen cible 95 millions de dollars de nouveaux projets d'innovation lors du premier appel avec un financement fédéral renouvelé. HAMILTON, Ontario, 27 mars 2023 (GLOBE NEWSWIRE) -- Fabrication de...